TRIALS deets

Question 1

Icotrokinra design?

Answer 1

Induction: randomized 2:1 to receive tx or placebo
Maintenance: clinical responders re-randomized, non-responders receive tx open-label

Question 2

Icotrokinra dose?

Answer 2

320mg

Question 3

What is icotrokinra?

Answer 3

IL-23 oral receptor antagonist

Question 4

Sanofi study?

Answer 4

TNF, allosterically binds soluble TNF

Question 5

Study design of Sanofi TNF?

Answer 5

randomized and blinded to 4 groups (200, 100BID, 100qd, placebo) 3:3:3:2
If clinically, worsen 200mg BID open label

Question 6

What is randomization of Sanofi TNF study?

Answer 6

3:3:3:2

Question 7

abbvie study design?

Answer 7

Risankizumab (anti-IL-23 p19 monoclonal antibody)
Risankizumab + ABBV-382 (anti-α4β7 integrin monoclonal antibody)
ABBV-382 (anti-α4β7 integrin monoclonal antibody)
Risankizumab + ABBV-8736 (anti-TREM1 monoclonal antibody)
ABBV-8736 (anti-TREM1 monoclonal antibody)

Question 8

Is abbvie study blinded?

Answer 8

No open label

Question 9

Abbvie study length

Answer 9

12 wk induction
12 wk open label maintenance
72 wk extension

Question 10

Randomization and dose for abbvie

Answer 10

1:1:1:1:1

Question 11

Icotrokinra study length

Answer 11

Induction 12wk
Maintenance 40wk

Question 12

Lily study design

Answer 12

Miri +/- tirzepatide
miri is OL

Question 13

Length of lily study

Answer 13

Open-label induction: 24 wk
Open-label maintenance: 28 wk
Blinded treatment component: Tirzepatide

Question 14

Roche what molecule

Answer 14

RO7837195, p40 and TL1A as a single bispecific antibody (IV, sc)

Question 15

roche study design

Answer 15

1000mg, 450, 150, 50, placebo
2:2:1:1:2

Question 16

roche study length

Answer 16

Induction: 12 wk
Maintenance: 40 wk

Question 17

Sanofi study specifi CD what is the cap

Answer 17

equal to or < 3 advance therapies, bio-naive eligible if 1 or > conventional therapy failed

Question 18

Abbvie cap?

Answer 18

eligible if failed one or more therapy (conventional or advanced)

Question 19

roche study cap?

Answer 19

Cap: ≤ 2 advanced therapies failed; bio-naïve eligible if ≥ 1 conventional therapy failed

Question 20

Iconic cap

Answer 20

Cap: ≥ 3 advanced therapies failures allowed (max 15%); UST failure max 20%; bio-naïve eligible if ≥ 1 conventional therapy failed

Question 21

Eli lilly cap?

Answer 21

Cap: ≤ 3 advanced therapies failed (UC only); eligible if failed ≥ 1 therapy (conventional or advanced)

Question 22

which studies are UC

Answer 22

Roche and iconic

Question 23

which are CD studies

Answer 23

Specifi sanofi
Abbvie
Lilly

Question 24

what is the abbvie molecule

Answer 24

risa (IL-23 p19 subunit)
abbv 382 (anti a4B7 integrin)
abbv 8736 anti TREM1